MariMed (MRMD) and Its Competitors Head-To-Head Contrast

MariMed (OTCMKTS:MRMDGet Rating) is one of 49 public companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare MariMed to similar companies based on the strength of its institutional ownership, analyst recommendations, dividends, earnings, risk, profitability and valuation.

Institutional and Insider Ownership

0.3% of MariMed shares are owned by institutional investors. Comparatively, 18.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 29.9% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares MariMed and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MariMed 5.70% 20.87% 6.07%
MariMed Competitors -184.32% -256.05% -16.54%

Analyst Recommendations

This is a summary of current recommendations and price targets for MariMed and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MariMed 0 0 2 0 3.00
MariMed Competitors 276 685 680 29 2.28

MariMed currently has a consensus target price of $2.25, indicating a potential upside of 254.47%. As a group, “Medicinals & botanicals” companies have a potential upside of 129.01%. Given MariMed’s stronger consensus rating and higher probable upside, analysts clearly believe MariMed is more favorable than its competitors.

Risk and Volatility

MariMed has a beta of 3.27, indicating that its share price is 227% more volatile than the S&P 500. Comparatively, MariMed’s competitors have a beta of 1.49, indicating that their average share price is 49% more volatile than the S&P 500.

Earnings and Valuation

This table compares MariMed and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MariMed $121.46 million $7.22 million 31.75
MariMed Competitors $238.87 million -$88.85 million -7.29

MariMed’s competitors have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


MariMed beats its competitors on 9 of the 13 factors compared.

About MariMed (Get Rating)

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with's FREE daily email newsletter.